{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:17:05Z","timestamp":1792588625071,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital of Sichuan University","doi-asserted-by":"publisher","award":["ZYGD23023"],"award-info":[{"award-number":["ZYGD23023"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573505"],"award-info":[{"award-number":["82573505"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2025NSFTD0030"],"award-info":[{"award-number":["2025NSFTD0030"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024NSFSC1931"],"award-info":[{"award-number":["2024NSFSC1931"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.apsb.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:43:16Z","timestamp":1780936996000},"page":"5405-5423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Universal off-the-shelf TGF-\u03b21-knockout whole-tumor cell vaccine overcomes immunotherapy resistance in pMMR\/MSS tumors"],"prefix":"10.1016","volume":"16","author":[{"given":"Weixiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2951-5150","authenticated-orcid":false,"given":"Zhexu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4600-9337","authenticated-orcid":false,"given":"Jiaqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5094-1376","authenticated-orcid":false,"given":"Hongxin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.06.001_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.06.001_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.06.001_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","article-title":"PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies","volume":"23","author":"Jin","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.06.001_bib5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: emerging immunological strategies","volume":"20","author":"Kubli","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.06.001_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.06.001_bib7","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.ccell.2025.05.010","article-title":"Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer","volume":"43","author":"Rousseau","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.06.001_bib8","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.21.02691","article-title":"Mismatch Repair-deficient colorectal cancer: building on checkpoint blockade","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib9","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Diaz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.001_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2026.06.001_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andre","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib13","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.001_bib14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II inspire trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib15","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Asaoka","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.001_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2026.06.001_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2026.06.001_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.apsb.2026.06.001_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.06.001_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","article-title":"Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development","volume":"26","author":"Huber","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.06.001_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.06.001_bib23","article-title":"VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens","volume":"15","author":"Carri","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.001_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41551-024-01309-0","article-title":"Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells","volume":"9","author":"Li","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.06.001_bib25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41587-023-01945-y","article-title":"Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types","volume":"42","author":"Gurung","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.06.001_bib26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s43018-025-00979-2","article-title":"Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer","volume":"6","author":"Apavaloaei","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2026.06.001_bib27","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/s41423-020-0456-1","article-title":"Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine","volume":"18","author":"Fang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2026.06.001_bib28","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.001_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.smim.2010.02.004","article-title":"Whole tumor antigen vaccines","volume":"22","author":"Chiang","year":"2010","journal-title":"Semin Immunol"},{"key":"10.1016\/j.apsb.2026.06.001_bib30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41467-019-14102-4","article-title":"Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.001_bib31","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-beta signaling in health and disease","volume":"186","author":"Massague","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.001_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGFbeta-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.06.001_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1126\/science.adg1955","article-title":"Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape","volume":"383","author":"Sharma","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.001_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.gastro.2024.02.025","article-title":"TGF-\u03b21-induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12","volume":"167","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2026.06.001_bib35","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1038\/s41388-023-02806-3","article-title":"ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer","volume":"42","author":"Zhang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.06.001_bib36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41392-023-01554-w","article-title":"Reduced smooth muscle-fibroblasts transformation potentially decreases intestinal wound healing and colitis-associated cancer in ageing mice","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.06.001_bib37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41568-025-00872-1","article-title":"The immune microenvironment of colorectal cancer","volume":"25","author":"Kennel","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.06.001_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.apsb.2024.12.017","article-title":"NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition","volume":"15","author":"Gao","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.06.001_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41571-023-00834-2","article-title":"Personalizing adjuvant therapy for patients with colorectal cancer","volume":"21","author":"Yang","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.06.001_bib41","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1039\/D5BM00914F","article-title":"Construction strategies of whole tumor cell vaccines","volume":"13","author":"Wang","year":"2025","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2026.06.001_bib42","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.06.001_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.canlet.2019.11.018","article-title":"Irradiated lactic acid-stimulated tumour cells promote the antitumour immunity as a therapeutic vaccine","volume":"469","author":"Yu","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.06.001_bib44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41540-024-00378-w","article-title":"Comprehensive molecular interaction map of TGF\u03b2 induced epithelial to mesenchymal transition in breast cancer","volume":"10","author":"Gottumukkala","year":"2024","journal-title":"npj Syst Biol Appl"},{"key":"10.1016\/j.apsb.2026.06.001_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0168-3659(03)00210-4","article-title":"GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer","volume":"91","author":"Nemunaitis","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.06.001_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cyto.2016.01.009","article-title":"Effects of tumor vaccine expressing granulocyte-macrophage colony stimulating factor and interleukin-18 fusion on cancer cells and its possible application for cancer immunotherapy","volume":"89","author":"Lee","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.apsb.2026.06.001_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines3020344","article-title":"Whole tumor antigen vaccines: where are we?.","volume":"3","author":"Chiang","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.apsb.2026.06.001_bib48","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.chembiol.2016.10.012","article-title":"Whole-cell cancer vaccines induce large antibody responses to carbohydrates and glycoproteins","volume":"23","author":"Xia","year":"2016","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2026.06.001_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2012.07.012","article-title":"Increasing the efficacy of tumor cell vaccines by enhancing cross priming","volume":"325","author":"Andersen","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.06.001_bib50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat Med"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:59:05Z","timestamp":1786219145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526003308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2211383526003308"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.06.001","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Universal off-the-shelf TGF-\u03b21-knockout whole-tumor cell vaccine overcomes immunotherapy resistance in pMMR\/MSS tumors","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}